Lexeo Therapeutics, Inc. Shares Outstanding (Cover Page)
Lexeo Therapeutics, Inc. (LXEO) had Shares Outstanding (Cover Page) of 82.05 million shares as of 2026-08-10, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-12
- 2026-08-10: Entity Common Stock, Shares Outstanding 82.05M shares.
- 2026-05-07: Entity Common Stock, Shares Outstanding 78.52M shares.
- 2026-03-27: Entity Common Stock, Shares Outstanding 74.09M shares.
- 2025-11-03: Entity Common Stock, Shares Outstanding 72.99M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-08-10 | 82.05M shares 10-Q · filed 2026-08-12 |
| 2026-05-07 | 78.52M shares 10-Q · filed 2026-05-11 |
| 2026-03-27 | 74.09M shares 10-K · filed 2026-03-30 |
| 2025-11-03 | 72.99M shares 10-Q · filed 2025-11-05 |
| 2025-08-12 | 54.00M shares 10-Q · filed 2025-08-14 |
| 2025-05-09 | 33.20M shares 10-Q/A · filed 2025-05-15 |
| 2025-03-21 | 33.20M shares 10-K · filed 2025-03-24 |
| 2024-11-11 | 33.07M shares 10-Q · filed 2024-11-13 |
| 2024-08-08 | 33.06M shares 10-Q · filed 2024-08-12 |
| 2024-05-07 | 32.95M shares 10-Q · filed 2024-05-09 |
| 2024-03-07 | 26.67M shares 10-K · filed 2024-03-11 |
| 2023-12-07 | 26.65M shares 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |